Allurion Technologies Inc. is cleared by regulators in France to resume sales of its swallowable gastric balloon to treat ...

The scientific establishment has launched a fight back against the Trump administration and the slew of executive orders that ...

New research has uncovered a complex interplay between extracellular matrix (ECM) structure and the transcriptional responses ...

European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech ...

Genescience Pharmaceuticals Co. Ltd. has prepared and tested new fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, ...

Ligachem Biosciences Inc. landed another exclusive licensing deal to develop and commercialize antibody-drug conjugates (ADCs ...

Coming as no surprise, the U.S. Senate’s Feb. 13 confirmation of Robert Kennedy as the next secretary of the Department of ...

Radiopharm Theranostics Ltd.’s radiotracer RAD-101 (F18-Pivalate) successfully detected brain metastases in a variety of primary solid tumors in a phase II study.

Brii Biosciences Inc. has identified substituted 2-(3,5-dichloro-4-(4-hydroxy-benzyl)phenoxy)acetamide derivatives that are prodrugs of thyroid hormone receptor β (TH-β) agonists and reported to be ...

The market took a strong liking to the latest U.S. FDA guidance for Moleculin Biotech Inc.’s upcoming Miracle phase III trial testing annamycin in cancer. So much so that the company’s stock ...

Heart disease remains the leading cause of death worldwide, and developing new therapeutic approaches constitutes an urgent healthcare priority. Almost one-third of patients surviving myocardial ...

Pliant Therapeutics Inc., which offered few details earlier this week when it voluntarily paused enrollment in the phase IIb Beacon-IPF trial testing bexotegrast in idiopathic pulmonary fibrosis (IPF) ...